Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) is a synthetic biology company that completed its SPAC merger with Soaring Eagle Acquisition Corp — sponsored by Eagle Equity Partners — in September 2021, bringing the Boston-based firm to public markets under the biotech and life sciences sector. The company, which operates a cell-programming platform serving pharmaceutical, agriculture, and industrial customers, filed an 8-K with the SEC on May 7, 2026 (accession 0001628280-26-032093), disclosing a material current event in the ordinary course of its public-company reporting obligations. DNA has traded as a de-SPAC since its merger closed and remains an actively tracked name in the SPAC research universe. Sign up at SpacDesk for full filing history, sponsor data, and real-time alerts on DNA and hundreds of other SPAC-linked companies.